Shares of Moderna tumbled in early trading Monday after the vaccine maker predicted a steeper-than-expected sales drop in the new year.
Moderna said it expects 2025 revenue to range between $1.5 billion and $2.5 billion after hitting as much as $3.1 billion last year.
Analysts expect, on average, $2.92 billion in revenue for 2025, according to FactSet.
The company also said it was speeding up and expanding a cost-cutting plan. It expects to cut cash costs by $1 billion in the new year, with additional cuts planned in 2026.
Moderna pulled in most of its revenue last year from its COVID-19 vaccine, Spikevax, which brought in more than $3 billion in sales. Regulators also approved a Moderna vaccine for RSV, or respiratory syncytial virus. The company said that generated minimal sales in the year.
Moderna made its announcement Monday ahead of a presentation at the annual J.P. Morgan Healthcare Conference in San Fransisco. The company will detail its fourth-quarter results on Feb. 14.
Moderna is a couple years removed from pulling in more than $19 billion in sales annually after initial vaccination rounds during the pandemic.
Shares of Cambridge, Massachusetts-based Moderna Inc. fell 19%, or $8.18, to $34.07 in morning trading.
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
